Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Eur J Med Chem. 2023 Dec 5;261:115866. doi: 10.1016/j.ejmech.2023.115866. Epub 2023 Oct 13.
Dual cyclooxygenase 2/15-lipoxygenase inhibitors constitute a valuable alternative to classical non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 (cyclooxygenase-2) inhibitors for the treatment of inflammatory diseases, as well as preventing the cancer. Indeed, these latter present diverse side effects, which are reduced or absent in dual-acting agents. In this review, COX-2 and 15-LOX (15-lipoxygenase) pathways are first described in order to highlight the therapeutic interest of designing such compounds. Various structural families of dual inhibitors are illustrated. This study discloses various structural families of dual 15-LOX/COX-2 inhibitors, thus pave the way to design potentially-active anticancer agents with balanced dual inhibition of these enzymes.
双重环氧化酶 2/15-脂氧合酶抑制剂是一种有价值的替代经典非甾体抗炎药（NSAIDs）和选择性 COX-2（环氧化酶-2）抑制剂，可用于治疗炎症性疾病，并预防癌症。事实上，这些后者存在多种副作用，而双重作用的药物则可以减少或消除这些副作用。在这篇综述中，首先描述了 COX-2 和 15-LOX（15-脂氧合酶）途径，以强调设计此类化合物的治疗意义。各种结构类型的双重抑制剂都有说明。本研究揭示了各种结构类型的双重 15-LOX/COX-2 抑制剂，为设计具有这些酶双重抑制作用的潜在活性抗癌药物铺平了道路。
